TSFAE23b:	Subjects With Related Fatal Treatment-emergent Adverse Events by Preferred Term; Safety Analysis Set (Study jjcs - core)					
 	Active Study Agent 	Active Study Agent 	Active Study Agent 	 	
 	Xanomeline High Dose 	Xanomeline Low Dose 	Combined 	Placebo 	
Preferred Term, n (%) 	N=53 	N=73 	N=126 	N=59 	
- No Data To Display -  	  	  	  	  	

Note: An AE is assessed by the investigator as related. Fatal AEs are based on AE outcome of Fatal. Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. 	
Note: An AE is assessed by the investigator as related. Fatal AEs are based on AE outcome of Fatal. Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: An AE is assessed by the investigator as related. Fatal AEs are based on AE outcome of Fatal. Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: An AE is assessed by the investigator as related. Fatal AEs are based on AE outcome of Fatal. Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: An AE is assessed by the investigator as related. Fatal AEs are based on AE outcome of Fatal. Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Adverse events are coded using MedDRA version 26.0. 	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.